RU2644160C2 - Химический способ - Google Patents

Химический способ Download PDF

Info

Publication number
RU2644160C2
RU2644160C2 RU2015104269A RU2015104269A RU2644160C2 RU 2644160 C2 RU2644160 C2 RU 2644160C2 RU 2015104269 A RU2015104269 A RU 2015104269A RU 2015104269 A RU2015104269 A RU 2015104269A RU 2644160 C2 RU2644160 C2 RU 2644160C2
Authority
RU
Russia
Prior art keywords
formula
compound
toluene
bromide
ethyl
Prior art date
Application number
RU2015104269A
Other languages
English (en)
Russian (ru)
Other versions
RU2015104269A (ru
Inventor
Фрэнк ХОССНЕР
Джон Брайс СТРЭЧЕН
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of RU2015104269A publication Critical patent/RU2015104269A/ru
Application granted granted Critical
Publication of RU2644160C2 publication Critical patent/RU2644160C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
RU2015104269A 2012-08-15 2013-08-14 Химический способ RU2644160C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683369P 2012-08-15 2012-08-15
US61/683,369 2012-08-15
PCT/EP2013/067035 WO2014027045A1 (en) 2012-08-15 2013-08-14 Chemical process

Publications (2)

Publication Number Publication Date
RU2015104269A RU2015104269A (ru) 2016-10-10
RU2644160C2 true RU2644160C2 (ru) 2018-02-08

Family

ID=49080842

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015104269A RU2644160C2 (ru) 2012-08-15 2013-08-14 Химический способ

Country Status (12)

Country Link
US (2) US9273001B2 (US07585860-20090908-C00162.png)
EP (2) EP2885298B1 (US07585860-20090908-C00162.png)
JP (2) JP6389174B2 (US07585860-20090908-C00162.png)
KR (1) KR20150043465A (US07585860-20090908-C00162.png)
CN (2) CN104619706B (US07585860-20090908-C00162.png)
AU (3) AU2013304102B2 (US07585860-20090908-C00162.png)
BR (1) BR112015003101B1 (US07585860-20090908-C00162.png)
CA (1) CA2881935A1 (US07585860-20090908-C00162.png)
ES (2) ES2893473T3 (US07585860-20090908-C00162.png)
IN (1) IN2015KN00323A (US07585860-20090908-C00162.png)
RU (1) RU2644160C2 (US07585860-20090908-C00162.png)
WO (1) WO2014027045A1 (US07585860-20090908-C00162.png)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148521B1 (en) 2014-05-28 2019-12-18 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
EP3215489B1 (en) 2014-11-03 2019-07-24 OLON S.p.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
CN108069956B (zh) * 2016-11-18 2021-03-16 扬州奥锐特药业有限公司 1-氮杂双环[2,2,2]辛-4-基苯基酮化合物及其制备方法和应用
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
CN107935917A (zh) * 2017-10-30 2018-04-20 广东莱佛士制药技术有限公司 一种1‑(2‑氯乙基)‑4‑哌啶甲酸酯的合成方法
CN109956938A (zh) * 2017-12-26 2019-07-02 天津金耀集团有限公司 乌美溴铵中间体晶型及其制备方法和以该中间体制备乌美溴铵的方法
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
PT115583B (pt) * 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
CN117310022B (zh) * 2023-09-22 2024-05-17 山东泰合医药科技有限公司 一种分离和检测乌美溴铵中间体奎宁环二苯甲醇有关物质的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601991A1 (ru) * 2004-04-27 2007-02-27 Глэксо Груп Лимитед Антагонисты мускариновых рецепторов ацетилхолина
WO2007036713A2 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Chemical process
WO2011029896A1 (en) * 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4540780A (en) * 1983-06-02 1985-09-10 Warner-Lambert Company Diphenylmethylene piperidines
FR2816618B1 (fr) * 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
JP4841279B2 (ja) * 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 被検物質の発がん性予測方法
SG192144A1 (en) * 2011-01-31 2013-08-30 Bristol Myers Squibb Co C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601991A1 (ru) * 2004-04-27 2007-02-27 Глэксо Груп Лимитед Антагонисты мускариновых рецепторов ацетилхолина
WO2007036713A2 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Chemical process
WO2011029896A1 (en) * 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists

Also Published As

Publication number Publication date
EP3401316A1 (en) 2018-11-14
AU2016213768B2 (en) 2018-01-04
EP2885298A1 (en) 2015-06-24
US20150232423A1 (en) 2015-08-20
US20160159786A1 (en) 2016-06-09
JP6799037B2 (ja) 2020-12-09
JP2015524832A (ja) 2015-08-27
AU2013304102B2 (en) 2016-09-01
IN2015KN00323A (US07585860-20090908-C00162.png) 2015-07-10
AU2013304102A1 (en) 2015-02-26
AU2016213768A1 (en) 2016-09-01
BR112015003101A2 (pt) 2017-07-04
AU2016262787A1 (en) 2016-12-15
CN104619706B (zh) 2017-06-20
CN107163038A (zh) 2017-09-15
CN107163038B (zh) 2020-07-28
EP2885298B1 (en) 2018-06-13
US9273001B2 (en) 2016-03-01
ES2893473T3 (es) 2022-02-09
KR20150043465A (ko) 2015-04-22
EP3401316B1 (en) 2021-08-04
CN104619706A (zh) 2015-05-13
US9657011B2 (en) 2017-05-23
RU2015104269A (ru) 2016-10-10
ES2678697T3 (es) 2018-08-16
BR112015003101B1 (pt) 2022-06-14
CA2881935A1 (en) 2014-02-20
JP6389174B2 (ja) 2018-09-12
WO2014027045A1 (en) 2014-02-20
JP2018203752A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
RU2644160C2 (ru) Химический способ
US8884016B2 (en) Apixaban preparation process
KR20210057032A (ko) 메틸 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디히드로-7h-벤조[7]아눌렌-2-카르복실레이트의 염 및 이의 제조 방법
CN109563066B (zh) 制备螺缩酮取代的环状酮烯醇的方法
JP2022533405A (ja) カンナビジオール系化合物の製造方法
US10562871B2 (en) Synthesis of sulfur containing ammonium and phosphonium borates
US20080167477A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
US20090203915A1 (en) Process for the preparation of solifenacin
US20100267954A1 (en) Process for the purification of paliperidone
KR102642754B1 (ko) 2-(2,6-디클로로페닐)-1-[(1s,3r)-3-(하이드록시메틸)-5-(3-하이드록시-3-메틸부틸)-1-메틸-3,4-디하이드로이소퀴놀린-2(1h)-일]에탄온의 제조를 위한 공정 및 중간체
WO2014079356A1 (zh) 恩曲他滨水杨酸盐及其晶型、制备方法和用途
US20090111849A1 (en) Crystalline salt of montelukast
KR20120053027A (ko) 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
KR102587674B1 (ko) 트레프로스티닐의 제조방법
US6433173B1 (en) Process for the preparation of ipidacrine or ipidacrine hydrochloride hydrate
WO2024171925A1 (ja) ビナフチル骨格を有するジエステル化合物の結晶及びその製造方法
US20200339561A1 (en) Process for the synthesis of 2-benzhydryl-3 quinuclidinone
TW201527266A (zh) 亞甲基二磺醯氯化合物之製造方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200815